Efficacy of transjugular intrahepatic portosystemic shunt in treatment of hepatocellular carcinoma comorbid with esophagogastric variceal bleeding
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 10
Abstract
[Objective] To investigate the efficacy of transjugular intrahepatic portosystemic shunt （TIPS） in preventing rebleeding in patients with hepatocellular carcinoma （HCC） comorbid with esophagogastric variceal bleeding and the influencing factors for prognosis. [Methods] A retrospective analysis was performed for the clinical data of 35 HCC patients comorbid with esophagogastric variceal bleeding who were admitted to Zengcheng Branch of Nanfang Hospital， Southern Medical University， and were treated with TIPS from July 2019 to April 2023. The Kaplan-Meier curve was used to assess rebleeding rate and survival rate after TIPS， and the Cox regression model was used to investigate the influencing factors for postoperative rebleeding and survival. [Results] The TIPS procedure was technically successful in all patients， with a median follow-up time of 16.4 months. During follow-up， 11 patients （31.4%） experienced esophagogastric variceal rebleeding， with the 1-month， 3-month， and 1-year rebleeding rates of 5.7%， 17.1%， and 28.6%， respectively. White blood cell count （WBC） （risk ratio ［HR］=1.31， 95% confidence interval ［CI］： 1.04 — 1.64， P=0.021）， number of tumors ≥3 （HR=35.68， 95%CI： 1.74 — 733.79， P=0.021）， and portal pressure gradient before TIPS （HR=0.85， 95%CI： 0.73 — 0.99， P=0.032） were independent predictive factors for rebleeding after TIPS. Shunt dysfunction was observed in 5 patients after surgery. A total of 19 patients died during follow-up， with a median survival time of 9.6 months. Portal vein tumor thrombosis （PVTT） （HR=7.04， 95%CI： 1.31 — 37.78， P=0.023）， total bilirubin （TBil） （HR=1.02， 95%CI： 1.00 — 1.03， P=0.042）， and serum albumin （HR=0.82， 95%CI： 0.72 — 0.94， P=0.004） were independent predictive factors for survival after TIPS. [Conclusion] TIPS procedure can be used as a therapeutic option to prevent esophagogastric variceal rebleeding in patients with HCC. Patients with a relatively high level of WBC or TBil or those with PVTT tend to have a poorer prognosis， and the application of TIPS treatment in such patients should be determined with caution.
Authors and Affiliations
Xiang GAO, Xiaofeng ZHANG, Yimin CAO, Jinjun CHEN, Xiaoqin LUO
Keywords
Related Articles
- EP ID EP751058
- DOI 10.12449/JCH241016
- Views 21
- Downloads 0
Role of peripheral clock genes in the progression， prevention， and treatment of nonalcoholic steatohepatitis
As a severe clinical manifestation of nonalcoholic fatty liver disease， nonalcoholic steatohepatitis （NASH） is characterized by lipid deposition and inflammatory damage in the liver. At present， clinical medications...
Value of liver biopsy in the diagnosis and clinical trial of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease （NAFLD） constitutes a series of histological lesions characterized by varying degrees of hepatocyte damage， fat accumulation， inflammation， and fibrosis. Currently， liver biopsy is...
The research on early-onset intrahepatic cholangiocarcinoma should be taken seriously
Intrahepatic cholangiocarcinoma （ICC） is a highly malignant biliary tumor， and early-onset ICC （EOICC） refers to ICC with an age of ≤50 years at the time of confirmed diagnosis and often has a higher clinical stage...
Influence of metabolism-related factors on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure and establishment of a predictive model
[Objective] To investigate the influence of metabolism-related factors （overweight and/or obesity， hyperglycemia， hypertension and dyslipidemia）on the 90-day prognosis of patients with hepatitis B virus-related acute...
Research advances in the pathogenesis of metabolic associated fatty liver disease
Metabolic associated fatty liver disease （MAFLD） is currently the most common liver disease around the world. MAFLD may easily progress to the adverse outcomes such as hepatitis， liver fibrosis， and liver cirrhosis，...